StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Rating) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.
TTNP opened at $0.82 on Tuesday. Titan Pharmaceuticals has a 52 week low of $0.80 and a 52 week high of $3.10. The business has a fifty day simple moving average of $0.99 and a 200-day simple moving average of $1.23.
A hedge fund recently raised its stake in Titan Pharmaceuticals stock. Morgan Stanley raised its holdings in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Rating) by 1,058,500.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,790 shares of the specialty pharmaceutical company’s stock after buying an additional 158,775 shares during the period. Morgan Stanley owned about 1.61% of Titan Pharmaceuticals worth $413,000 as of its most recent SEC filing. 17.59% of the stock is owned by hedge funds and other institutional investors.
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union.
- Get a free copy of the StockNews.com research report on Titan Pharmaceuticals (TTNP)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.